• Disposable Autoinjectors Market is Anticipated to reach US$ 172.3 Bn and expanding at a CAGR of 18.1% over the forecast years (2022-2030) - R&I

    The global disposable autoinjectors market in 2020 is estimated for more than US$ 45.7 Bn and expected to reach at a value of US$ 172.3 Bn by 2028 with a significant CAGR of 18.1%.

    Request a Sample Copy of this Report @: https://reportsandinsights.com/sample-request/1339

    Disposable Autoinjectors Market is Anticipated to reach US$ 172.3 Bn and expanding at a CAGR of 18.1% over the forecast years (2022-2030) - R&I The global disposable autoinjectors market in 2020 is estimated for more than US$ 45.7 Bn and expected to reach at a value of US$ 172.3 Bn by 2028 with a significant CAGR of 18.1%. Request a Sample Copy of this Report @: https://reportsandinsights.com/sample-request/1339
    0 Comments 0 Shares
  • NOVEL OCULAR DRUG DELIVERY MARKET – GROWING INTEREST IN THE PHARMACEUTICAL INDUSTRY AND THE GROWING FUTURE POTENTIAL

    The Novel Ocular Drug Delivery Devices Market report features an extensive study of the current market landscape and the likely adoption of novel ocular drug delivery devices, over the next decade. The study features a detailed analysis of the key drivers and trends related to this evolving domain.

    According to the World Health Organization (WHO), more than 2.2 billion individuals across the world suffer from some degree of vision impairment caused due to various ophthalmic disorders, such as glaucoma, trachoma, cataract, diabetic retinopathy and wet age-related macular degeneration. Around 50% of the cases are left either unaddressed and / or could have been prevented. It is also worth highlighting that around 1.7 billion individuals worldwide are expected to lose their vision by 2050. As per the Centers for Disease Control and Prevention (CDC), loss of vision can pose an economic burden of over USD 35 billion, in terms of loss of productivity and direct costs of treatment / care. Considering the aforementioned facts, there is a rise in demand for effective therapeutic interventions for the treatment of ocular diseases, in order to prevent complete vision loss. Conventionally, ocular diseases have been treated through surgery, laser or pharmacological interventions (such as anti-angiogenic drugs). However, these treatment options are associated with several limitations, including side effects of intravitreal injections and conventional surgeries, poor drug bioavailability at the target tissue site and need for frequent drug administration to maintain efficacy for a longer duration. In addition, at present, more than 90% of the marketed ophthalmic formulations are available in the form of eye drops that mainly target diseases related to anterior segment of the eye. Studies suggest that, if administered with the help of topical eye drops, around 95% of the drug is lost due to a number of challenges, such as dilution of product by tears and permeation issues related to cornea. Therefore, drug delivery formulations, such as eye drops and ointments, cannot be considered as an optimal treatment option for vision-threatening diseases.

    To request a sample report: https://www.rootsanalysis.com/reports/novel-ocular-drug-delivery-devices-market/request-sample.html
    Owing to the concerns, there is an evident rise in the demand for effective, non-invasive drug delivery systems that are capable of overcoming bioavailability hurdles and enable delivery of the drug at the target cells, at effective concentrations, for a suitable period of time. Over time, several pharmaceutical companies across the world have undertaken various initiatives to develop novel drug delivery devices, such as sustained release implants, ocular inserts and punctal plugs, that are capable of enabling effective administration of drugs, while overcoming the existing challenges. In fact, over 1,100 patents related to novel ocular drug delivery devices have been filed / granted in the past few years, demonstrating the continued innovation being carried out in this domain.

    To order customize report: https://www.rootsanalysis.com/reports/novel-ocular-drug-delivery-devices-market/request-customization.html

    Based on the type of ocular disorders, therapeutics can be delivered into the ocular regions. The selection of appropriate route of administration for a particular drug, depends on the target ocular tissue.

    The growing interest of pharmaceutical stakeholders in this field is also reflected from the recent rise in partnership activity of novel ocular drug delivery device developers. Driven by the increasing patient population and introduction of novel and advanced ocular drug delivery devices, this market is anticipated to witness steady growth in the coming years.

    For more information, please click on the following link:
    https://www.rootsanalysis.com/reports/novel-ocular-drug-delivery-devices-market.html

    You may also be interested in the following reports:
    1. Container Closure Integrity Testing Services Market
    2. Global Autoinjectors Market
    3. Large Volume Wearable Injectors Market
    4. At-Home Blood Collection and Micro Sampling Devices Market


    About Roots Analysis
    Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

    Contact Information
    Roots Analysis Private Limited
    Ben Johnson
    +1 (415) 800 3415
    ben.johnson@rootsanalysis.com
    Facebook - https://www.facebook.com/RootsAnalysis
    LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/
    Twitter - https://twitter.com/RootsAnalysis
    Medium - https://medium.com/@RootsAnalysis
    Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/
    Quora - https://rootsanalysisinsights.quora.com/
    NOVEL OCULAR DRUG DELIVERY MARKET – GROWING INTEREST IN THE PHARMACEUTICAL INDUSTRY AND THE GROWING FUTURE POTENTIAL The Novel Ocular Drug Delivery Devices Market report features an extensive study of the current market landscape and the likely adoption of novel ocular drug delivery devices, over the next decade. The study features a detailed analysis of the key drivers and trends related to this evolving domain. According to the World Health Organization (WHO), more than 2.2 billion individuals across the world suffer from some degree of vision impairment caused due to various ophthalmic disorders, such as glaucoma, trachoma, cataract, diabetic retinopathy and wet age-related macular degeneration. Around 50% of the cases are left either unaddressed and / or could have been prevented. It is also worth highlighting that around 1.7 billion individuals worldwide are expected to lose their vision by 2050. As per the Centers for Disease Control and Prevention (CDC), loss of vision can pose an economic burden of over USD 35 billion, in terms of loss of productivity and direct costs of treatment / care. Considering the aforementioned facts, there is a rise in demand for effective therapeutic interventions for the treatment of ocular diseases, in order to prevent complete vision loss. Conventionally, ocular diseases have been treated through surgery, laser or pharmacological interventions (such as anti-angiogenic drugs). However, these treatment options are associated with several limitations, including side effects of intravitreal injections and conventional surgeries, poor drug bioavailability at the target tissue site and need for frequent drug administration to maintain efficacy for a longer duration. In addition, at present, more than 90% of the marketed ophthalmic formulations are available in the form of eye drops that mainly target diseases related to anterior segment of the eye. Studies suggest that, if administered with the help of topical eye drops, around 95% of the drug is lost due to a number of challenges, such as dilution of product by tears and permeation issues related to cornea. Therefore, drug delivery formulations, such as eye drops and ointments, cannot be considered as an optimal treatment option for vision-threatening diseases. To request a sample report: https://www.rootsanalysis.com/reports/novel-ocular-drug-delivery-devices-market/request-sample.html Owing to the concerns, there is an evident rise in the demand for effective, non-invasive drug delivery systems that are capable of overcoming bioavailability hurdles and enable delivery of the drug at the target cells, at effective concentrations, for a suitable period of time. Over time, several pharmaceutical companies across the world have undertaken various initiatives to develop novel drug delivery devices, such as sustained release implants, ocular inserts and punctal plugs, that are capable of enabling effective administration of drugs, while overcoming the existing challenges. In fact, over 1,100 patents related to novel ocular drug delivery devices have been filed / granted in the past few years, demonstrating the continued innovation being carried out in this domain. To order customize report: https://www.rootsanalysis.com/reports/novel-ocular-drug-delivery-devices-market/request-customization.html Based on the type of ocular disorders, therapeutics can be delivered into the ocular regions. The selection of appropriate route of administration for a particular drug, depends on the target ocular tissue. The growing interest of pharmaceutical stakeholders in this field is also reflected from the recent rise in partnership activity of novel ocular drug delivery device developers. Driven by the increasing patient population and introduction of novel and advanced ocular drug delivery devices, this market is anticipated to witness steady growth in the coming years. For more information, please click on the following link: https://www.rootsanalysis.com/reports/novel-ocular-drug-delivery-devices-market.html You may also be interested in the following reports: 1. Container Closure Integrity Testing Services Market 2. Global Autoinjectors Market 3. Large Volume Wearable Injectors Market 4. At-Home Blood Collection and Micro Sampling Devices Market About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact Information Roots Analysis Private Limited Ben Johnson +1 (415) 800 3415 ben.johnson@rootsanalysis.com Facebook - https://www.facebook.com/RootsAnalysis LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/ Twitter - https://twitter.com/RootsAnalysis Medium - https://medium.com/@RootsAnalysis Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/ Quora - https://rootsanalysisinsights.quora.com/
    Request Sample - Novel Ocular Drug Delivery Devices | Market Size | Industry Analysis | 2030
    Novel Ocular Drug Delivery Devices Market report features an extensive study of the current market landscape and future potential of the...
    WWW.ROOTSANALYSIS.COM
    0 Comments 0 Shares
  • PRE-STERILIZED / READY-TO-USE PRIMARY PACKAGING MARKET - CURRENT MARKET LANDSCAPE
    Presently, more than 150 pre-sterilized / RTU primary packaging systems, including cartridges, syringes, and vials, as well as their respective closure systems are available worldwide. Majority (50%) of the pre-sterilized / RTU primary packaging systems are closures, followed by containers (34%) and container-closure systems (16%). It is worth highlighting that, of the total, 54 closures are suitable for use with vials, 19 are suitable for use with syringes and the remaining 5 are compatible with cartridges.
    To request a sample report: https://www.rootsanalysis.com/reports/224/request-sample.html

    Amongst the primary packaging containers, vials and syringes emerged as the most common types of pre-sterilized / RTU containers manufactured by stakeholders engaged in this domain. This can be attributed to the fact that these containers are the most suitable for packaging of small volume of therapeutics, such as biologics, cell therapies, small molecules, vaccines, and other potent products.

    Further, glass emerged as the most preferred fabrication material used for pre-sterilized / RTU containers. Of these, majority (83%) of the containers are made of type I borosilicate glass, followed by those fabricated using type II treated soda-lime glass (10%) and type III soda-lime glass (7%). This is followed by pre-sterilized / RTU containers fabricated using plastic (29%), primarily cyclic olefin polymer. Examples include (in alphabetical order) ClearVial (MedicoPack), Daikyo Crystal Zenith Insert Needle Syringe Systems (Daikyo Seiko), Daikyo Crystal Zenith Ready to Use Vials (Daikyo Seiko) and SCHOTT TopPac sensitive (SCHOTT).

    To order customize report: https://www.rootsanalysis.com/reports/224/request-customization.html

    Sterilization of primary packaging systems is considered to be an essential step in the overall healthcare manufacturing process as it deactivates various forms of contaminating agents (particularly referring to bacteria, fungi, protozoa and viruses). Majority (43%) of the pre-sterilized / RTU containers are sterilized using ethylene oxide, followed by those employing steam sterilization (34%).

    Presently, close to 50 companies claim to be actively involved in the manufacturing of pre-sterilized / RTU primary packaging systems. The market landscape is highly fragmented, featuring a mix of small (less than 50 employees, 17%), mid-sized (51-500 employees, 37%), large (501-1,000 employees, 2%) and very large (more than 1,000 employees, 44%) companies. The pre-sterilized / RTU packaging manufacturers market is fragmented, featuring the presence of established players as well as new entrants, which are well distributed across different geographical regions. Examples of established players include (in decreasing order of experience) Gerresheimer (1864), Sartorius (1870), SCHOTT (1884), DWK Life Sciences (1887), SGD Pharma (1896) and Becton, Dickinson, and Company (1897).

    For more information, please click on the following link:
    https://www.rootsanalysis.com/reports/view_document/pre-sterilized-ready-to-use-primary-packaging-market/224.html

    You may also be interested in the following reports:
    1. Container Closure Integrity Testing Services Market
    2. Global Autoinjectors Market
    3. Large Volume Wearable Injectors Market
    4. Genome Editing Services Market

    Contact Information
    Roots Analysis Private Limited
    Ben Johnson
    +1 (415) 800 3415
    ben.johnson@rootsanalysis.com
    Facebook - https://www.facebook.com/RootsAnalysis
    LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/
    Twitter - https://twitter.com/RootsAnalysis
    Medium - https://medium.com/@RootsAnalysis
    Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/
    Quora - https://rootsanalysisinsights.quora.com/
    PRE-STERILIZED / READY-TO-USE PRIMARY PACKAGING MARKET - CURRENT MARKET LANDSCAPE Presently, more than 150 pre-sterilized / RTU primary packaging systems, including cartridges, syringes, and vials, as well as their respective closure systems are available worldwide. Majority (50%) of the pre-sterilized / RTU primary packaging systems are closures, followed by containers (34%) and container-closure systems (16%). It is worth highlighting that, of the total, 54 closures are suitable for use with vials, 19 are suitable for use with syringes and the remaining 5 are compatible with cartridges. To request a sample report: https://www.rootsanalysis.com/reports/224/request-sample.html Amongst the primary packaging containers, vials and syringes emerged as the most common types of pre-sterilized / RTU containers manufactured by stakeholders engaged in this domain. This can be attributed to the fact that these containers are the most suitable for packaging of small volume of therapeutics, such as biologics, cell therapies, small molecules, vaccines, and other potent products. Further, glass emerged as the most preferred fabrication material used for pre-sterilized / RTU containers. Of these, majority (83%) of the containers are made of type I borosilicate glass, followed by those fabricated using type II treated soda-lime glass (10%) and type III soda-lime glass (7%). This is followed by pre-sterilized / RTU containers fabricated using plastic (29%), primarily cyclic olefin polymer. Examples include (in alphabetical order) ClearVial (MedicoPack), Daikyo Crystal Zenith Insert Needle Syringe Systems (Daikyo Seiko), Daikyo Crystal Zenith Ready to Use Vials (Daikyo Seiko) and SCHOTT TopPac sensitive (SCHOTT). To order customize report: https://www.rootsanalysis.com/reports/224/request-customization.html Sterilization of primary packaging systems is considered to be an essential step in the overall healthcare manufacturing process as it deactivates various forms of contaminating agents (particularly referring to bacteria, fungi, protozoa and viruses). Majority (43%) of the pre-sterilized / RTU containers are sterilized using ethylene oxide, followed by those employing steam sterilization (34%). Presently, close to 50 companies claim to be actively involved in the manufacturing of pre-sterilized / RTU primary packaging systems. The market landscape is highly fragmented, featuring a mix of small (less than 50 employees, 17%), mid-sized (51-500 employees, 37%), large (501-1,000 employees, 2%) and very large (more than 1,000 employees, 44%) companies. The pre-sterilized / RTU packaging manufacturers market is fragmented, featuring the presence of established players as well as new entrants, which are well distributed across different geographical regions. Examples of established players include (in decreasing order of experience) Gerresheimer (1864), Sartorius (1870), SCHOTT (1884), DWK Life Sciences (1887), SGD Pharma (1896) and Becton, Dickinson, and Company (1897). For more information, please click on the following link: https://www.rootsanalysis.com/reports/view_document/pre-sterilized-ready-to-use-primary-packaging-market/224.html You may also be interested in the following reports: 1. Container Closure Integrity Testing Services Market 2. Global Autoinjectors Market 3. Large Volume Wearable Injectors Market 4. Genome Editing Services Market Contact Information Roots Analysis Private Limited Ben Johnson +1 (415) 800 3415 ben.johnson@rootsanalysis.com Facebook - https://www.facebook.com/RootsAnalysis LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/ Twitter - https://twitter.com/RootsAnalysis Medium - https://medium.com/@RootsAnalysis Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/ Quora - https://rootsanalysisinsights.quora.com/
    Request Sample - Pre-Sterilized Ready-to-Use Primary Packaging - Focus on Cartridges Syringes Vials and Closures (2nd Edition) 2021-2030 | Industry Analysis | Market Size | 2030
    Market Research Report on Pre-Sterilized / Ready-to-Use Primary Packaging: Focus on Cartridges, Syringes and Vials..
    WWW.ROOTSANALYSIS.COM
    0 Comments 0 Shares

No results to show

No results to show

No results to show

No results to show

Sponsored